⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BYSI News
BeyondSpring Inc. Ordinary Shares
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
globenewswire.com
BYSI
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
globenewswire.com
BYSI
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
BYSI